Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III (ATIII) and accelerates its inhibition of thrombin (factor IIa) and other serine proteases (factors Xa, IXa, XIa, XIIa) in the coagulation cascade, thereby preventing fibrin clot formation.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; subsequent dose adjusted based on aPTT. Typical infusion rate: 20,000–40,000 units/24 hours.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
Terminal elimination half-life is 1-2 hours at therapeutic doses, dose-dependent: 30-60 min after IV bolus of 25 U/kg, increasing to 1.5-2.5 hours after 400 U/kg. Prolonged in hepatic/renal impairment and pulmonary embolism. Clinical context: continuous infusion achieves steady-state after ~4-6 hours.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Heparin is eliminated primarily via hepatic metabolism and renal excretion. Approximately 50% of a dose undergoes hepatic desulfation and depolymerization to form uroheparin, which is excreted in urine. Unchanged heparin is cleared renally via saturable, dose-dependent mechanisms. Biliary/fecal elimination is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant